To identify common genetic architectures linking psychoactive substance use (PSU) and cancer through a genome-wide association study (GWAS), highlighting the significance of understanding their relationship.
Key Findings:
Identification of shared genetic loci and hub genes between PSU and various cancers, with implications for understanding cancer risk.
Causal effects of alcohol use dependence (AlcUD) and nicotine use dependence (NicUD) on cancer risk were established.
Hub genes primarily expressed in the brain cerebellum were identified as potential druggable targets, suggesting avenues for therapeutic intervention.
Interpretation:
The findings suggest a genetic overlap between PSU and cancer, indicating that genetic predispositions may contribute to both conditions and highlighting potential targets for therapeutic intervention.
Limitations:
Observational studies may have residual confounding and measurement errors, which could affect the results.
The complexity of genetic interactions and environmental factors may obscure true relationships, and biases in GWAS methodology should be considered.
Conclusion:
This study provides insights into the shared genetic architecture of PSU and cancer, potentially guiding future research and therapeutic strategies, emphasizing the need for further investigation.
The goal of this clinical trial is to evaluate if adaptive stereotactic body radiation therapy (SBRT) is a safe and effective way to treat prostate cancer in adults. It will assess the safety profile of adaptive SBRT over time.
